"Understanding and targeting Alzheimer´s disease"

5-8 May 2019, Rungstedgaard, North of Copenhagen, Denmark

Co-chairs:
Christian Haass, LMU Munich & German Center for Neurodegenerative Diseases, Germany and Beth Stevens, Harvard Medical School, USA

Go to application

Dementia poses one of the largest health and economic problems in the world with over 50 million people worldwide living with dementia, no disease modifying treatments available, and numbers set to dramatically increase as our population ages. Neuroscience research has the real potential to change this bleak future and develop effective ways to prevent or treat the diseases that cause dementia.

Three of our current grand challenges towards this goal are to understand why certain brain regions are susceptible to the accumulation of pathology and neurodegeneration early in Alzheimer’s disease and related dementias, how pathologies then spread from these vulnerable regions to damage the rest of the brain, and finally how risk factors like ApoE modulate disease progression.

In this meeting, we will address the best way to move forward as a field in addressing these knowledge gaps with an emphasis on the emerging data in the field implicating non-neuronal contributors to disease risk and regional vulnerability.  The latest clinical trials and the requirement of biomarkers for early risk assessment will be discussed on the background of our understanding of disease mechanisms.  The meeting will end with a podiums discussion on the pros and cons of the amyloid cascade hypothesis.


Speakers overview

Maria Grazia Spillantini, University of Cambridge, UK
Michel Goedert, MRC Laboratory of Molecular Biology, UK
Lennart Mucke, Gladstone Institutes of Neurological Disease, USA
Tara Spires-Jones, University of Edinburgh, UK
John Hardy, University College London, UK
Mathias Jucker, University of Tübingen, Germany
Marc Diamond, UT Southwestern Medical Center, USA
Melanie Meyer-Lühmann, Albert-Ludwigs-Universität Freiburg, Germany
Dorothee Dormann, Ludwig Maximilian University of Munich, Germany
Bart De Strooper, VIB-KU Leuven, Belgium
Arthur Konnerth, Technical University of Munich, Germany
Robert Vassar, Northwestern University, USA
Dennis Selkoe, Harvard Medical School, Center for Neurologic Diseases , USA

Adriano Aguzzi, Institute of Neuropathology, University Hospital Zurich, Switzerland
Matthias Mann, Max Planck Institute of Biochemsitry, Germany
Beth Stevens, Harvard Medical School, USA

Christian Haass, LMU Munich & German Center for Neurodegenerative Diseases, Germany
Ido Amit, Weizmann Institute of Science, Israel
Li Gan, Gladstone Institutes of Neurological Disease, UCSF, USA
Maiken Nedergaard, University of Rochester Medical Center/University of Copenhagen, USA/Denmark
Marco Colonna Washington University in St. Louis, USA

Jonathan Kipnis,University of Virginia School of Medicine, USA
Dennis Selkoe, Harvard Medical School, Center for Neurologic Diseases , USA
John Hardy, University College London, UK

The Lundbeck foundation have 20 free seats to the conference in May.

To be considered, the applicant must be based in Denmark, below 40 years, bring an abstract and participate in the entire meeting.

You can apply by sending an e-mail to thebrainprize@lundbeckfonden.com with name, title, institution and age.
Deadline is 18 February 2019

It will be first come, first serve and we will inform the applicants after the deadline by mail whether they have received a free seat or not. The list of applicants will be forwarded to the FENS organizers.


The applicants must then register themselves and enclose their abstract using the go-to-the-application link above to FENS Brain conference.

 

Scherfigsvej 7
2100 Copenhagen Ø
Denmark
Tel. +45 39 12 80 00
CVR-nr. 11 81 49 13
thebrainprize@lundbeckfonden.com
www.thebrainprize.org
Nils Axelsen Ralf Hemmingsen Lauritz Holm-Nielsen Ralf Hemmingsen Jens Oddershede Jens Frederik Rehfeld Anders Bjørklund